Drug price hikes without new evidence upped spending by $1.2B
The Institute for Clinical and Economic Review (ICER) published its second-ever report on Unsupported Price Increases (UPI) last week, compiled from data [...]
Value-Based Purchasing Rule For Medicaid Rx Drugs
Writing in Health Affairs, outgoing CMS Administrator Seema Verma touts how the Trump Administration helped paved the way for more [...]
Democrats Have Their Best Shot Yet at Letting Medicare Negotiate Drug Prices
Democrats have their best shot in more than a decade to deliver on one of the party’s central health care [...]
How a Former Health Care Executive Became a Health Care Whistleblower
Former health care executive Wendell Potter spent part of 2020 publishing high-profile apologies for the work he used to do — the lies [...]
(Podcast) Bridge the City: Opportunity Costs of Healthcare in the US
Researchers David Vanness and James Lomas joined the Bridge the City podcast to explain the conclusions of their new paper, [...]
[Podcast] How Doctors Can Be a Part of the Solution
In the final episode of our podcast's inaugural season, neurologist Jason Crowell and ICER's President Steve Pearson discuss what physicians [...]
State Level Action in Response to ICER’s Unsupported Price Increase Report
In ICER’s latest report on Unsupported Price Increases (UPI), we determined that 7 of the 10 costliest US drug-price hikes [...]
New Data Show Retail Medicine Prices Fell in 2019
In 2019, retail prescription medicine prices declined by 0.4%, on average, according to National Health Expenditures (NHE) data from the Centers for Medicare & [...]
Implications of Price Transparency for Providers and Patients as New Rules Go into Effect
A new KFF analysis examines how new federal rules on price transparency for health services may affect patient decision-making and [...]
Specialty Generics Face Perverse Incentives In Medicare Part D
Whether specialty generics are cheaper to payers than their originator branded counterparts is partly a function of the level of [...]
Drugmakers Raise Prices 3.3% in the New Year
This month pharmaceutical companies have increased list prices on hundreds of branded drugs -- mostly between 2-7% (with only a [...]
ICER Identifies Most Significant 2019 US Drug-Price Hikes
The Institute for Clinical and Economic Review (ICER) today published its latest report on Unsupported Price Increases (UPI) of prescription [...]
EQRx Scales Disruptive Model of Important New Medicines
EQRx, a company committed to developing and delivering important new medicines at lower prices, today announced that it has raised [...]
Seniors Face Crushing Drug Costs as Congress Stalls on Capping Medicare Out-Of-Pockets
Unlike private health insurance, Medicare Part D drug plans have no cap on patients’ 5% coinsurance costs once they hit [...]
The Bane of Prior Authorization
In a STAT op-ed, Brian Barnett, a psychiatrist at the Cleveland Clinic, discusses the burden of completing prior authorizations to [...]
Has COVID-19 Changed Prescription Drug Pricing Forever?
As the COVID-19 pandemic continues to disrupt our lives and health care system on a historic scale, it is worth [...]
ICER To Release Final Assessment of Selected High-impact Drugs
ICER will be reviewing changes in the evidence base for each of these drugs and assess whether or not new [...]
RxSense Joins with Hy-Vee to Launch New PBM Vivid Clear Rx
RxSense was founded in 2015 with a singular focus on developing technology solutions that improve healthcare transparency and access to [...]
Hospitals Lose Another Attempt to Stave Off Price Transparency
A federal appeals court ruled against hospitals' efforts to stop regulators from forcing them to reveal the secret negotiated prices [...]
How Does Cost-Sharing Impact Spending Growth and Cost-Effective Treatments?
The growth of health care spending has been a longstanding policy concern. Over the years, several innovations have been proposed [...]
Drug Wholesale Prices Impact Payer Spending, Out-of-pocket Costs
Increases in drug wholesale list prices have a trickle-down effect that negatively impacts patient financial responsibility, such as out-of-pocket costs, [...]
Reshaping of Global Policy by COVID: Implications for Market Access
The COVID-19 pandemic has upended daily lives around the globe and has also created new challenges for life sciences companies [...]
CMS Announces Drug Payment Reductions with the “Most Favored Nation” Effective January 1, 2021
Centers for Medicare and Medicaid Services (CMS) announced the long-awaited seven year Most Favored Nation (MFN) model as an interim [...]
Balancing Lower U.S. Prescription Drug Prices And Innovation
This Health Affairs blog post provides background on U.S. drug prices and summarizes an expert roundtable discussion held in June [...]
[Podcast] From Pharma to the Medicine Cabinet: Who Manages the Drugs?
Drugmakers, pharmacies, wholesale distributors, physicians, pharmacy benefit managers—the world of prescription drugs can seem extraordinarily complex. In Episode 3 of [...]